MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 12-16-2023
Biohaven Pharmaceutical Holding Company Ltd. Revenue 2011-2026 | BHVN
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Biohaven Pharmaceutical Holding Company Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 463 M | 63.6 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 463 M | 63.6 M | 263 M |
Quarterly Revenue Biohaven Pharmaceutical Holding Company Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 319 M | - | 136 M | 92.9 M | 43.8 M | 35.1 M | 17.7 M | 9.7 M | 1.15 M | -1.77 M | - | - | - | -742 K | -697 K | -641 K | -728 K | -681 K | -638 K | -348 K | -218 K | -172 K | -75 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 319 M | -1.77 M | 34.1 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B |  USA |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
Autolus Therapeutics plc
AUTL
|
75.4 M | $ 1.34 | -3.6 % | $ 357 M |  Britain |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | USA |
 |
DBV Technologies S.A.
DBVT
|
5.64 M | $ 20.13 | -1.13 % | $ 2.81 B | France |
 |
Alterity Therapeutics Limited
ATHE
|
109 K | $ 3.65 | 1.3 % | $ 8.78 B |  Australia |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
Dyadic International
DYAI
|
3.09 M | $ 0.87 | - | $ 31.5 M | USA |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
66.4 M | $ 2.57 | -3.57 % | $ 16.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Equillium
EQ
|
41.1 M | $ 2.04 | 1.24 % | $ 117 M | USA |
 |
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K | USA |
 |
Fate Therapeutics
FATE
|
6.65 M | $ 1.13 | -5.04 % | $ 134 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
Forte Biosciences
FBRX
|
18 M | $ 26.57 | 0.49 % | $ 344 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
44.6 M | $ 6.14 | -4.36 % | $ 175 M | USA |
|
Foghorn Therapeutics
FHTX
|
30.9 M | $ 4.74 | -2.87 % | $ 299 M | USA |
 |
AIkido Pharma
AIKI
|
123 M | - | 1.93 % | $ 17.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
634 M | $ 14.46 | 0.03 % | $ 4.46 B | USA |
 |
Fulcrum Therapeutics
FULC
|
80 M | $ 7.55 | -3.58 % | $ 478 K | USA |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
482 M | $ 87.65 | -3.98 % | $ 27.2 B | Germany |
 |
Gilead Sciences
GILD
|
29.4 B | $ 138.19 | -1.38 % | $ 172 B | USA |
 |
Coherus BioSciences
CHRS
|
42.2 M | $ 1.61 | -3.59 % | $ 189 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
2.04 M | $ 0.54 | 4.26 % | $ 503 K |  Israel |
 |
Genmab A/S
GMAB
|
10.1 B | $ 27.01 | -2.67 % | $ 17.2 B |  Danmark |
 |
Alnylam Pharmaceuticals
ALNY
|
3.71 B | $ 314.44 | -4.81 % | $ 41.2 B | USA |
 |
Gossamer Bio
GOSS
|
48.5 M | $ 0.32 | -7.11 % | $ 73.1 M | USA |
 |
Grifols, S.A.
GRFS
|
7.21 B | $ 7.91 | -3.95 % | $ 6.83 B |  Spain |
 |
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | USA |
 |
GT Biopharma
GTBP
|
27 K | $ 0.42 | -6.49 % | $ 2.32 M | USA |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Halozyme Therapeutics
HALO
|
1.4 B | $ 63.51 | 0.68 % | $ 7.61 B | USA |
 |
Burford Capital Limited
BUR
|
330 M | $ 4.42 | -1.34 % | $ 727 M | Britain |